UBS Group set a CHF 87 price target on Novartis (VTX:NOVN) in a research note released on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Several other equities analysts have also issued reports on the company. HSBC set a €101.00 ($117.44) price target on Grenke and gave the company a buy rating in a research note on Thursday, April 25th. Credit Suisse Group decreased their price target on FOX from $51.00 to $45.00 and set an outperform rating on the stock in a research note on Monday, June 3rd. JPMorgan Chase & Co. set a €50.00 ($58.14) price target on Brenntag and gave the company a buy rating in a research note on Tuesday, July 16th. Barclays reiterated a buy rating and issued a $417.00 price target on shares of Boeing in a research note on Monday, April 8th. Finally, Jefferies Financial Group boosted their price objective on Nice to $166.00 and gave the stock a buy rating in a research report on Thursday, May 16th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of CHF 88.64.
Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.
Novartis Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Further Reading: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.